Ivan Špıčka

15.6k total citations · 2 hit papers
141 papers, 3.7k citations indexed

About

Ivan Špıčka is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Ivan Špıčka has authored 141 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 131 papers in Hematology, 83 papers in Oncology and 81 papers in Molecular Biology. Recurrent topics in Ivan Špıčka's work include Multiple Myeloma Research and Treatments (129 papers), Protein Degradation and Inhibitors (51 papers) and Peptidase Inhibition and Analysis (48 papers). Ivan Špıčka is often cited by papers focused on Multiple Myeloma Research and Treatments (129 papers), Protein Degradation and Inhibitors (51 papers) and Peptidase Inhibition and Analysis (48 papers). Ivan Špıčka collaborates with scholars based in Czechia, United States and Spain. Ivan Špıčka's co-authors include Pieter Sonneveld, Antonio Palumbo, Andrew Spencer, María‐Victoria Mateos, Tamás Masszi, Roman Hájek, Meral Beksaç, Katja Weisel, William Deraedt and Jesús F. San Miguel and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Ivan Špıčka

126 papers receiving 3.6k citations

Hit Papers

Daratumumab, Bortezomib, and Dexamethasone fo... 2007 2026 2013 2019 2016 2007 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
    2016 1.1k citations Antonio Palumbo, Tamás Masszi et al. profile →
  2. Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy Improves Time to Progression
    2007 505 citations Robert Z. Orlowski, Pieter Sonneveld et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ivan Špıčka Czechia 24 3.1k 2.4k 2.1k 474 249 141 3.7k
William Deraedt United States 15 2.2k 0.7× 1.7k 0.7× 1.5k 0.7× 410 0.9× 225 0.9× 56 2.7k
Antonio Palumbo Italy 34 3.5k 1.1× 2.6k 1.1× 2.0k 1.0× 485 1.0× 286 1.1× 131 4.0k
Jeffrey A. Zonder United States 35 2.7k 0.9× 2.9k 1.2× 1.9k 0.9× 661 1.4× 330 1.3× 194 4.6k
Jean‐Luc Harousseau France 20 2.6k 0.8× 2.2k 0.9× 1.6k 0.8× 425 0.9× 218 0.9× 45 3.4k
Donna M. Weber United States 28 2.7k 0.9× 2.4k 1.0× 1.6k 0.8× 616 1.3× 251 1.0× 132 3.6k
Hareth Nahi Sweden 30 2.0k 0.7× 1.6k 0.7× 1.5k 0.7× 437 0.9× 559 2.2× 143 3.0k
Martin Kropff Germany 26 2.5k 0.8× 2.1k 0.9× 1.7k 0.8× 368 0.8× 155 0.6× 69 3.1k
H M Lokhorst Netherlands 35 2.3k 0.7× 1.7k 0.7× 1.5k 0.7× 402 0.8× 583 2.3× 80 3.6k
Robert M. Rifkin United States 26 1.6k 0.5× 1.4k 0.6× 1.2k 0.5× 248 0.5× 347 1.4× 143 2.5k
Dixie‐Lee Esseltine United States 22 2.5k 0.8× 2.3k 1.0× 1.6k 0.8× 406 0.9× 135 0.5× 38 3.2k

Countries citing papers authored by Ivan Špıčka

Since Specialization
Citations

This map shows the geographic impact of Ivan Špıčka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ivan Špıčka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ivan Špıčka more than expected).

Fields of papers citing papers by Ivan Špıčka

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ivan Špıčka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ivan Špıčka. The network helps show where Ivan Špıčka may publish in the future.

Co-authorship network of co-authors of Ivan Špıčka

This figure shows the co-authorship network connecting the top 25 collaborators of Ivan Špıčka. A scholar is included among the top collaborators of Ivan Špıčka based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ivan Špıčka. Ivan Špıčka is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rückert, Michael, Mamta Garg, Ceri Bygrave, et al.. (2024). Evolution of Treatment Patterns and Survival Outcomes in European Patients with Multiple Myeloma from 2012-2023 through the Honeur Federated Data Network. Blood. 144(Supplement 1). 2388–2388.
2.
Façon, Thierry, Meletios Α. Dimopoulos, Xavier Leleu, et al.. (2024). Phase 3 study results of isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) versus VRd for transplant-ineligible patients with newly diagnosed multiple myeloma (IMROZ).. Journal of Clinical Oncology. 42(16_suppl). 7500–7500. 3 indexed citations
3.
Kapoor, Prashant, Nitya Nathwani, Tomáš Jelı́nek, et al.. (2024). An open‐label, first‐in‐human, single agent, dose escalation study for the evaluation of safety and efficacy of SAR442085 in patients with relapsed or refractory multiple myeloma. European Journal Of Haematology. 113(5). 593–605. 1 indexed citations
4.
Richardson, Paul G., Aurore Perrot, Joseph Mıkhael, et al.. (2024). Allocation and validation of the second revision of the International Staging System in the ICARIA-MM and IKEMA studies. Blood Cancer Journal. 14(1). 209–209. 3 indexed citations
5.
Špıčka, Ivan, Maximilian Merz, Jakub Radocha, et al.. (2023). P944: REAL-WORLD PATIENT CHARACTERISTICS AND SURVIVAL OUTCOMES OF LENALIDOMIDE REFRACTORY VS. LENALIDOMIDE EXPOSED RRMM PATIENTS IN THE HONEUR FEDERATED DATA NETWORK. HemaSphere. 7(S3). e258126d–e258126d. 2 indexed citations
6.
Štork, Martin, Ivan Špıčka, Jakub Radocha, et al.. (2023). Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients – real world evidence analysis. Annals of Hematology. 102(6). 1501–1511. 6 indexed citations
7.
Perrot, Aurore, Paul G. Richardson, Joseph Mıkhael, et al.. (2023). P968: ALLOCATION AND VALIDATION OF THE SECOND REVISION OF THE INTERNATIONAL STAGING SYSTEM IN THE ICARIA-MM AND IKEMA STUDIES. HemaSphere. 7(S3). e3398301–e3398301. 1 indexed citations
8.
Pour, Luděk, Ivan Špıčka, Jakub Radocha, et al.. (2023). P1294: REAL-WORLD OUTCOMES OF 2149 NEWLY DIAGNOSED TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA PATIENTS. HemaSphere. 7(S3). e0151603–e0151603. 1 indexed citations
9.
Štork, Martin, Sabina Ševčı́ková, Tomáš Jelı́nek, et al.. (2022). Unexpected Heterogeneity of Newly Diagnosed Multiple Myeloma Patients with Plasmacytomas. Biomedicines. 10(10). 2535–2535. 2 indexed citations
10.
Maisnar, Vladimír, Luděk Pour, Ivan Špıčka, et al.. (2022). Patient Characteristics, Treatment Patterns, and Outcomes in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma Patients, a Retrospective Observational Study Using Czech Registry Data. Clinical Lymphoma Myeloma & Leukemia. 23(2). 145–153. 4 indexed citations
11.
Minařík, Jiří, Jakub Radocha, Alexandra Jungová, et al.. (2022). Ixazomib, Lenalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma in Routine Clinical Practice: Extended Follow-Up Analysis and the Results of Subsequent Therapy. Cancers. 14(20). 5165–5165. 5 indexed citations
12.
Paiva, Bruno, Irene Manrique, Meletios Α. Dimopoulos, et al.. (2022). MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials. Blood. 141(6). 579–591. 25 indexed citations
13.
Dimopoulos, Meletios Α., Ivan Špıčka, Hang Quach, et al.. (2020). Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial. Journal of Clinical Oncology. 38(34). 4030–4041. 53 indexed citations
14.
Hájek, Roman, Luděk Pour, Muhıt Özcan, et al.. (2019). A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma. European Journal Of Haematology. 104(5). 435–442. 12 indexed citations
15.
Ludwig, Heinz, Luísa Viterbo, Richard Greil, et al.. (2012). Randomized Phase II Study of Bortezomib, Thalidomide, and Dexamethasone With or Without Cyclophosphamide As Induction Therapy in Previously Untreated Multiple Myeloma. Journal of Clinical Oncology. 31(2). 247–255. 58 indexed citations
16.
Němec, Pavel, Zuzana Zemanová, Petr Kuglík, et al.. (2011). Complex karyotype and translocation t(4;14) define patients with high-risk newly diagnosed multiple myeloma: results of CMG2002 trial. Leukemia & lymphoma. 53(5). 920–927. 34 indexed citations
17.
Štraub, Jan, et al.. (2009). Mnohočetný myelom - časná diagnostika. 6(4). 197–199.
18.
Ludwig, Heinz, Roman Hájek, Elena Tóthová, et al.. (2008). Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma. Blood. 113(15). 3435–3442. 148 indexed citations
19.
Palumbo, Antonio, Rudolf Schlag, Nuriet K. Khuageva, et al.. (2008). Prolonged therapy with bortezomib plus melphalan-prednisone (vmp) results in improved quality and duration of response in the phase iii vista study in previously untreated multiple myeloma (mm). 93. 83–83. 7 indexed citations
20.
Mokrejšová, Magdaléna, et al.. (2000). [Disorders of urinary acidification in patients with monoclonal gammapathies].. PubMed. 139(20). 638–42. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by William Deraedt Breakdown of academic impact, for papers by Antonio Palumbo Breakdown of academic impact, for papers by Jeffrey A. Zonder Breakdown of academic impact, for papers by Jean‐Luc Harousseau Breakdown of academic impact, for papers by Donna M. Weber Breakdown of academic impact, for papers by Hareth Nahi Breakdown of academic impact, for papers by Martin Kropff Breakdown of academic impact, for papers by H M Lokhorst Breakdown of academic impact, for papers by Robert M. Rifkin Breakdown of academic impact, for papers by Dixie‐Lee Esseltine
Rankless by CCL
2026